AR7 — RARα antagonist
Product Name :
AR7 — RARα antagonist
Description:
AR7 was developed as a highly potent and selective enhancer of the chaperone-mediated autophagy (CMA) through antagonizing RARα. It is a synthetic derivative of all-trans-retinoic acid developed through the structure-based chemical design. CMA contributes to cellular quality control and the cellular response to stress through the selective degradation of cytosolic proteins in lysosomes. A decrease in CMA activity occurs in aging and in age-related disorders (such as neurodegenerative diseases and diabetes). AR7 is the first small molecule developed to selectively stimulate CMA without affecting macroautophagy. Importantly, AR7 was shown to protect cells from oxidative stress and proteotoxicity, presenting a potential therapeutic strategy against cellular dysfunction and disease resulted from reduced CMA.
CAS:
80306-38-3
Molecular Weight:
257.71
Formula:
C15H12ClNO
Chemical Name:
7-chloro-3-(p-tolyl)-2H-benzo[b][1,4]oxazine
Smiles :
CC1C=CC(=CC=1)C1COC2=CC(Cl)=CC=C2N=1
InChiKey:
MVOZLTFXYGHZPM-UHFFFAOYSA-N
InChi :
InChI=1S/C15H12ClNO/c1-10-2-4-11(5-3-10)14-9-18-15-8-12(16)6-7-13(15)17-14/h2-8H,9H2,1H3
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.{{Renilla-Firefly Luciferase Dual Assay Kit} web|{Renilla-Firefly Luciferase Dual Assay Kit} NF-κB|{Renilla-Firefly Luciferase Dual Assay Kit} Technical Information|{Renilla-Firefly Luciferase Dual Assay Kit} In Vivo|{Renilla-Firefly Luciferase Dual Assay Kit} custom synthesis}
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.{{Sertraline} medchemexpress|{Sertraline} Neuronal Signaling|{Sertraline} Biological Activity|{Sertraline} Data Sheet|{Sertraline} supplier|{Sertraline} Epigenetic Reader Domain}
Additional information:
AR7 was developed as a highly potent and selective enhancer of the chaperone-mediated autophagy (CMA) through antagonizing RARα.PMID:24268253 It is a synthetic derivative of all-trans-retinoic acid developed through the structure-based chemical design. CMA contributes to cellular quality control and the cellular response to stress through the selective degradation of cytosolic proteins in lysosomes. A decrease in CMA activity occurs in aging and in age-related disorders (such as neurodegenerative diseases and diabetes). AR7 is the first small molecule developed to selectively stimulate CMA without affecting macroautophagy. Importantly, AR7 was shown to protect cells from oxidative stress and proteotoxicity, presenting a potential therapeutic strategy against cellular dysfunction and disease resulted from reduced CMA.|Product information|CAS Number: 80306-38-3|Molecular Weight: 257.71|Formula: C15H12ClNO|Synonym:|AR-7|AR 7|AR7|Atypical retinoid 7|Chemical Name: 7-chloro-3-(p-tolyl)-2H-benzo[b][1,4]oxazine|Smiles: CC1C=CC(=CC=1)C1COC2=CC(Cl)=CC=C2N=1|InChiKey: MVOZLTFXYGHZPM-UHFFFAOYSA-N|InChi: InChI=1S/C15H12ClNO/c1-10-2-4-11(5-3-10)14-9-18-15-8-12(16)6-7-13(15)17-14/h2-8H,9H2,1H3|Technical Data|Appearance: Solid Power.|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO up to 100 mM|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined.|HS Tariff Code: 382200|How to use|In Vitro:|AR7 was suggested to be used at 5-20 µM final concentration in vitro and in cellular assays.|References:|Anguiano J, et al. Chemical modulation of chaperone-mediated autophagy by retinoic acid derivatives. (2013) Nat Chem Biol. 9(6):374-82.Products are for research use only. Not for human use.|